Other Cipla Medicines and Product Areas
Cipla is often encountered in searches for sildenafil, tadalafil, and other urology products, but those medicines represent only one part of a much broader pharmaceutical portfolio. Current Cipla materials describe activity across respiratory care, HIV and antiviral treatment, cardiometabolic medicine, urology, anti-infectives, oncology, child health, ophthalmology, women’s health, neuropsychiatry, and other therapeutic areas.
This page focuses on product and therapy categories rather than repeating the company history covered on the main Cipla Limited hub. Product availability, brand names, strengths, and regulatory status vary by market, so examples below are tied to current Cipla or regulator materials rather than treated as a universal global catalog.
Respiratory Medicines
Respiratory care remains one of Cipla’s most prominent therapy areas. Current corporate materials describe a portfolio that spans inhaled medicines and drug-device combinations for asthma and chronic obstructive pulmonary disease. Cipla’s respiratory history includes pressurized metered-dose inhalers, dry-powder inhalers, nebulized products, and breath-actuated delivery systems.
Current Cipla market pages also show how the exact product mix changes by country. Cipla Spain, for example, currently lists respiratory products involving budesonide/formoterol, fluticasone, ipratropium, ipratropium/salbutamol, salmeterol/fluticasone, and other respiratory ingredients. Those examples establish current portfolio activity in that market; they should not be read as a list of products available from every Cipla subsidiary or pharmacy.
Cipla’s 2025–26 corporate reporting also continues to identify respiratory medicine as a major therapy area, while the company’s development pipeline includes additional inhaled products and devices. A user researching a Cipla inhaler should therefore identify the exact active ingredients, device type, strength, and country rather than searching by manufacturer alone.
HIV and Antiviral Medicines
Cipla has a long history in HIV treatment and continues to maintain an active global-access portfolio. Current corporate reporting identifies tenofovir/lamivudine/dolutegravir 300/300/50 mg as a major regimen in its global-access business and describes continuing development of long-acting and tenofovir-alafenamide-based HIV products.
Cipla’s broader therapy information also includes hepatitis and antiviral categories. In specific markets, current Cipla product catalogs may include individual antiviral ingredients. For example, Cipla Spain lists tenofovir disoproxil and valganciclovir among current products.
These examples should be interpreted by market. An HIV or antiviral medicine may be supplied through public-health programs, national tenders, hospital channels, or retail prescription markets depending on the country. A global corporate portfolio does not establish ordinary retail availability in Portland or elsewhere in the United States.
Cardiometabolic Medicines
Cardio-metabolism is another current Cipla therapy area. Cipla’s generics portfolio lists anti-hypertension, cardiac, and anti-diabetic categories, while current corporate reporting identifies cardiology and anti-diabetes among important chronic-therapy businesses.
For consumers, the useful product question is usually more specific than “Cipla heart medicine.” A current prescription may involve an antihypertensive, lipid-lowering medicine, antiplatelet product, diabetes therapy, or another cardiometabolic drug. The ingredient and exact product determine the regulatory record and comparison—not the fact that Cipla participates broadly in cardiometabolic medicine.
Because portfolios differ by country, this reference does not reproduce a long list of brand names from one market and imply that the same list applies globally. Users comparing a Cipla generic should match the active ingredient, strength, dosage form, labeler, and market.
Urology Products
Cipla’s current therapy information identifies urology as a significant product area. The company describes activity in benign prostatic hyperplasia, prostate cancer, bladder disorders, urinary stones, hypogonadism, and sexual dysfunction.
Current Cipla materials specifically mention bicalutamide for prostate cancer and potassium citrate plus magnesium citrate solution for urinary-stone management. Cipla also has documented product activity involving alpha-blockers and combination products used in BPH care.
Sexual-health searches form another branch of the urology portfolio. Separate pages on this site cover Cipla sildenafil products, Cipla tadalafil products, and Cipla testosterone and other sexual-health products. Those product-focused pages preserve the distinctions among ingredients, indications, dosage forms, and markets.
Anti-Infective Medicines
Cipla’s current generics and therapy pages list anti-infectives, antibiotics, antifungals, antiparasitic products, and related categories. The exact mix again varies by country.
As one current market example, Cipla Spain lists anti-infective products involving daptomycin, ertapenem, posaconazole, tenofovir disoproxil, and valganciclovir. These examples show the breadth of the anti-infective portfolio but should not be converted into a blanket statement that all of those products are marketed by Cipla in the United States.
Anti-infective product identification is particularly sensitive to dosage form, route, strength, and approved indication. A hospital injectable and an oral retail product can belong to the same broad therapy area while having very different distribution and prescribing contexts.
Oncology and Other Therapeutic Areas
Oncology is an active Cipla business area. In September 2026, Cipla USA announced the U.S. launch of pomalidomide capsules in 1 mg, 2 mg, 3 mg, and 4 mg strengths as a generic equivalent of Pomalyst. That is a current U.S.-specific example and is more informative than an undated global brand list.
Cipla Spain currently lists oncology products involving abiraterone, bevacizumab, bexarotene, and methotrexate, again demonstrating how regional portfolios differ. Cipla’s current corporate materials also describe continued investment in oncology development and licensing.
Beyond oncology, current Cipla therapy pages include women’s health, ophthalmology, neuropsychiatry, child health, and infectious diseases and critical care. Its generics catalog also spans pain, gastrointestinal, dermatology, vitamins, thyroid management, and other categories.
The purpose of listing these areas is not to create an enormous catalog. It is to help a user recognize that a Cipla label can belong to a wide range of medicines, many unrelated to the company’s better-known respiratory or urology products.
How to Identify a Cipla Medicine
When a patient or purchaser has a Cipla product name but is unsure what it is, the most useful information is on the current package and label. Record:
- the exact product or generic name;
- active ingredient or combination of ingredients;
- strength or concentration;
- dosage form and route;
- manufacturer, distributor, or labeler;
- NDC, registration number, or other market-specific product identifier;
- country in which the package was supplied.
A brand name alone may be insufficient because Cipla’s branded-generics strategy can use market-specific names. Conversely, a generic name alone may identify the ingredient but not the particular manufacturer or pack.
Why Cipla Product Lists Differ by Country
Cipla’s business model combines branded medicines, generics, regional subsidiaries, public-health supply, and country-specific regulatory portfolios. A respiratory brand visible on an Indian or Spanish Cipla page may therefore have no identical U.S. product name, while a Cipla USA generic may be sold simply under the active ingredient. The manufacturer relationship can be real in both cases without the products being commercially identical.
This is why a current portfolio reference should use regional examples sparingly and label them by market. It also explains why old global-looking product lists become inaccurate: launches, licensing agreements, discontinuations, and national registrations change independently.
Product Availability and Regulatory Status
Cipla’s global portfolio should not be treated as a single worldwide inventory. A product may be registered in one market, discontinued in another, or marketed under a different company or labeler in a third. U.S. product questions should be checked through current FDA and labeling records; other countries have their own regulators and product databases.
Approval also does not equal pharmacy stock. A drug can have a current regulatory record while a particular pharmacy does not carry it, and a product can remain visible in search engines after a manufacturer has reduced supply or discontinued a pack.
For this reason, Paulsen’s Pharmacy does not use this reference page to claim current stock, online fulfillment, or guaranteed pricing for Cipla products. A current access question needs the exact product details and a real-time pharmacy check.
Cipla Product Reference
For manufacturer-level background and navigation, return to Cipla Limited. The dedicated child pages are more useful when the search is already specific to sildenafil, tadalafil, or testosterone/sexual-health products.
Across all of these categories, the same identification rule applies: manufacturer, active ingredient, strength, dosage form, market, and regulatory record should agree before two product names are treated as equivalent.
Reviewed by: Dr. Nancy Ann Curosh